Professor at the School of Law at the University of Washington and an associate director at the Institute for Public Health Genetics at the University of Washington.
Director of policy and government relations at BluePath Health.
Ethics Hum Res. 2020 Jul;42(4):2-16. doi: 10.1002/eahr.500058.
The near-routine exclusion of pregnant women from clinical research has resulted in evidence gaps that endanger the health of pregnant women and their future offspring. Although existing literature documents numerous obstacles along the clinical trial pathway that can stymie research involving pregnant women, there is little guidance on how to facilitate such research. This qualitative study aims to fill that void by examining the experiences of individuals involved in conducting, approving, or overseeing research involving pregnant women at one academic institution. The study identifies factors throughout the clinical pathway-from protocol development, to IRB review, and ultimately trial execution-that likely contribute to the successful conduct of research with pregnant women. Attention to those factors, coupled with agreement among stakeholders that research with pregnant women should and can be done ethically and legally, is critical to shifting the narrative from "why we cannot" do such research to "how we can."
将孕妇排除在临床研究之外已成为常态,这导致了危及孕妇及其后代健康的证据空白。尽管现有文献记录了临床研究路径中许多可能阻碍涉及孕妇的研究的障碍,但关于如何促进此类研究的指导却很少。这项定性研究旨在通过研究一家学术机构中参与进行、批准或监督涉及孕妇的研究的个人的经验来填补这一空白。该研究确定了临床途径中从方案制定到 IRB 审查,最终到试验执行的各个因素,这些因素可能会对成功进行涉及孕妇的研究产生影响。关注这些因素,以及利益相关者之间的共识,即研究涉及孕妇应该而且可以在伦理和法律上进行,对于从“为什么我们不能”进行此类研究转变为“我们如何能够”进行此类研究至关重要。